Vimarsana
Biggest News Aggregation in the World

Page 8 - Medication Guidefor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medication Guidefor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medication Guidefor Today - Breaking & Trending Today

New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks - Vimarsana News

New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks

Published: February 18, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 2b QUASAR Induction Study 1. Results showed a...

Source: prnewswire.com
Related Topics:
United StatesSpring HouseBritish ColumbiaAxel DignassJan WehkampBridget KimmelGoethe University In FrankfurtNone Of The Janssen Pharmaceutical CompaniesJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonHead Of The Department MedicineExchange CommissionEuropean UnionCompanies Of JohnsonColitis OrganisationEuropean CrohnAgaplesion Markus HospitalGoethe UniversityVice PresidentGastroenterology Disease Area LeaderJanssen ResearchJanssen Global TrialPrescribing InformationMedication Guidefor
New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks - Vimarsana News

New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks

Published: February 18, 2022

SPRING HOUSE, Pa., Feb. 18, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase ...

Source: businessinsider.com
Related Topics:
United StatesSpring HouseBritish ColumbiaAxel DignassJan WehkampBridget KimmelGoethe University In FrankfurtNone Of The Janssen Pharmaceutical CompaniesCrohn Colitis FoundationDrug AdministrationJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonHead Of The Department MedicineExchange CommissionEuropean UnionCompanies Of JohnsonColitis OrganisationEuropean CrohnAgaplesion Markus HospitalGoethe UniversityVice PresidentGastroenterology Disease Area LeaderJanssen ResearchJanssen Global Trial
The Majority of Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA® (guselkumab) - Vimarsana News

The Majority of Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA® (guselkumab)

Published: February 18, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new results from the Phase 2 GALAXI 1 clinical trial showing the...

Source: prnewswire.com
Related Topics:
Spring HouseBritish ColumbiaUnited StatesJan WehkampBridget KimmelNone Of The Janssen Pharmaceutical CompaniesJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonExchange CommissionEuropean UnionCompanies Of JohnsonDisease Activity Index WeekReported OutcomeVice PresidentGastroenterology Disease Area LeaderJanssen ResearchJanssen Global TrialLeast Squares MeanAbout CrohnPrescribing InformationMedication GuideforReversible Encephalopathy SyndromeMedication GuidePharmaceutical Companies
The Majority of Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA® (guselkumab) - Vimarsana News

The Majority of Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA® (guselkumab)

Published: February 18, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new results from the Phase 2 GALAXI 1 clinical trial showing the...

Source: prnewswire.com
Related Topics:
Spring HouseBritish ColumbiaUnited StatesJan WehkampBridget KimmelNone Of The Janssen Pharmaceutical CompaniesJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonExchange CommissionEuropean UnionCompanies Of JohnsonDisease Activity Index WeekReported OutcomeVice PresidentGastroenterology Disease Area LeaderJanssen ResearchJanssen Global TrialLeast Squares MeanAbout CrohnPrescribing InformationMedication GuideforReversible Encephalopathy SyndromeMedication GuidePharmaceutical Companies
New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks - Vimarsana News

New Phase 2b Data Show the Majority of Adults with Moderately to Severely Active Ulcerative Colitis Achieved Clinical Response with TREMFYA® (guselkumab) at 12 Weeks

Published: February 18, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 2b QUASAR Induction Study 1. Results showed a...

Source: prnewswire.com
Related Topics:
United StatesSpring HouseBritish ColumbiaAxel DignassJan WehkampBridget KimmelGoethe University In FrankfurtNone Of The Janssen Pharmaceutical CompaniesJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonHead Of The Department MedicineExchange CommissionEuropean UnionCompanies Of JohnsonColitis OrganisationEuropean CrohnAgaplesion Markus HospitalGoethe UniversityVice PresidentGastroenterology Disease Area LeaderJanssen ResearchJanssen Global TrialPrescribing InformationMedication Guidefor